Brolucizumab Switch and Extend Ph IIIb Study: A Canadian, multi-center, single-arm, open label study assessing the efficacy and safety of brolucizumab 6mg in a Treat and Extend regimen in patients with nAMD with prior anti-VEGF exposure (PEREGRINE)
Research Grant
Administered By
Ophthalmology
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
October 6, 2020
End Date
July 29, 2022
Administered By
Ophthalmology
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
October 6, 2020
End Date
July 29, 2022